Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin
versus bevacizumab with capecitabine and oxaliplatin for
metastatic colorectal carcinoma: results of a large
registry-based cohort analysis

J 2014

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

BUCHLER, Tomáš; Tomáš PAVLÍK; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Zuzana USIAKOVÁ et al.

Základní údaje

Originální název

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Autoři

Vydání

BMC CANCER, London, BIOMED CENTRAL LTD, 2014, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.362

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00075704

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Colorectal cancer; Bevacizumab; Capecitabine; 5-fluorouracil; Oxaliplatin

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 4. 2015 13:07, Soňa Böhmová

Anotace

V originále

Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progression-free survival (PFS) was 11.4 months (95% CI 10.7-12.1 months) for FOLFOX/bevacizumab and 11.5 months (95% CI 10.8-12.3 months) for XELOX/bevacizumab (p = 0.337). The number of metastatic sites was identified as the most significant predictor of PFS and, together with the presence/absence of metastatic disease at diagnosis, also for OS. Conclusions: According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone chemotherapy regimen.

Citovat

BUCHLER, Tomáš; Tomáš PAVLÍK; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Zuzana USIAKOVÁ; Ladislav DUŠEK; Igor KISS; Milan KOHOUTEK; Vera BENESOVA; Rostislav VYZULA; Jitka ABRAHAMOVA a Radka OBERMANNOVA. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC CANCER. London: BIOMED CENTRAL LTD, 2014, roč. 14, "article number" 323, s. 1-7. ISSN 1471-2407. Dostupné z: https://doi.org/10.1186/1471-2407-14-323.

@article{1185592,
   author = {Buchler, Tomáš and Pavlík, Tomáš and Melichar, Bohuslav and Bortlíček, Zbyněk and Usiaková, Zuzana and Dušek, Ladislav and Kiss, Igor and Kohoutek, Milan and Benesova, Vera and Vyzula, Rostislav and Abrahamova, Jitka and Obermannova, Radka},
   article_location = {London},
   article_number = {"article number" 323},
   doi = {https://doi.org/10.1186/1471-2407-14-323},
   keywords = {Colorectal cancer; Bevacizumab; Capecitabine; 5-fluorouracil; Oxaliplatin},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC CANCER},
   title = {Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis},
   volume = {14},
   year = {2014}
}

TY  - JOUR
ID  - 1185592
AU  - Buchler, Tomáš - Pavlík, Tomáš - Melichar, Bohuslav - Bortlíček, Zbyněk - Usiaková, Zuzana - Dušek, Ladislav - Kiss, Igor - Kohoutek, Milan - Benesova, Vera - Vyzula, Rostislav - Abrahamova, Jitka - Obermannova, Radka
PY  - 2014
TI  - Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
JF  - BMC CANCER
VL  - 14
IS  - "article number" 323
SP  - 1-7
EP  - 1-7
PB  - BIOMED CENTRAL LTD
SN  - 14712407
KW  - Colorectal cancer
KW  - Bevacizumab
KW  - Capecitabine
KW  - 5-fluorouracil
KW  - Oxaliplatin
N2  - Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progression-free survival (PFS) was 11.4 months (95% CI 10.7-12.1 months) for FOLFOX/bevacizumab and 11.5 months (95% CI 10.8-12.3 months) for XELOX/bevacizumab (p = 0.337). The number of metastatic sites was identified as the most significant predictor of PFS and, together with the presence/absence of metastatic disease at diagnosis, also for OS. Conclusions: According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone chemotherapy regimen.
ER  -

BUCHLER, Tomáš; Tomáš PAVLÍK; Bohuslav MELICHAR; Zbyněk BORTLÍČEK; Zuzana USIAKOVÁ; Ladislav DUŠEK; Igor KISS; Milan KOHOUTEK; Vera BENESOVA; Rostislav VYZULA; Jitka ABRAHAMOVA a Radka OBERMANNOVA. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. \textit{BMC CANCER}. London: BIOMED CENTRAL LTD, 2014, roč.~14, ''article number'' 323, s.~1-7. ISSN~1471-2407. Dostupné z: https://doi.org/10.1186/1471-2407-14-323.

Přehled o publikaci